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httpcense.Abstract Background: Conventional TB diagnosis continues to rely on smear microscopy, culture
and chest radiography. Other non-conventional approaches include detection of immunological
response and the search for biochemical markers. Cancer antigen 125 (Ca-125) was evaluated
mainly in patients with extra pulmonary TB.
Objective: This study was designed to detect the role of Ca-125 in differentiating pulmonary
tuberculosis from other pulmonary infections. Also to determine the value of Ca-125 was an indi-
cator of response to anti-tuberculous drugs.
Design: Eighty patients were included in the study, 27 with active pulmonary TB and 33 with
other pulmonary infections. Twenty healthy volunteers were used as a control group. Measurement
of serum Ca-125 was performed once in all groups, it was re-assayed after 4 months of anti-tuber-
culous drugs among patients with active pulmonary TB.
Results: There was a signiﬁcant increase of Ca-125 among patients with active pulmonary TB
than the other groups, which decrease signiﬁcantly after anti-tuberculous drugs. The sensitivity
and speciﬁcity of Ca-125 were found to be 81.4% and 95%, respectively, at a 34.6 U/ml cut-off
point.
Conclusion: Ca-125 can be a useful marker in differentiating pulmonary TB from other pulmon-
ary infections and in assessment the response to anti-tuberculoussis drugs.
ª 2013 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V.Open access under CC BY-NC-ND license.2355846.
(A.F. Said).
he Egyptian Society of Chest
g by Elsevier
of Chest Diseases and Tuberculos
://dx.doi.org/10.1016/j.ejcdt.2013.0Introduction
Tuberculosis represents an important health problem world-
wide that was declared by World Health Organization
(WHO) to be global emergency [1]. The World Health Organi-
zation estimates that each year more than 8 million new cases
of tuberculosis occur and approximately 3 million persons die
from the disease. Ninety-ﬁve percent of tuberculosis cases
occur in developing countries [2].is. Production and hosting by Elsevier B.V.
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HIV and Mycobacterium tuberculosis, with the majority living
in sub-Saharan Africa and Southeast Asia [3].
TB currently holds the seventh place in the global ranking
of causes of death. Unless intensive efforts are made, it is likely
to maintain that position through to 2020 [4].
Pulmonary TB, the most important type of TB from the
public health point of view, can be diagnosed by its symptoms,
chest radiography, sputum smear microscopy, and by cultiva-
tion of M. tuberculosis [5].
However, in some cases of pulmonary TB, acid-fast bacilli
stains in sputum samples may be negative or respiratory spec-
imens may not be available, and other methods have to be used
to establish the diagnosis of TB.
Recent advances in the ﬁeld of molecular biology have pro-
vided new tools for the rapid diagnosis of TB by molecular
methods. However, the high cost of most of these techniques,
and their requirement for sophisticated equipment or highly
skilled personnel have precluded their implementation on a
routine basis, especially in low-income countries [6].
Apart from microbiological molecular diagnostic tests, dif-
ferent biochemical parameters have been proposed as helpful
tools for this purpose, including various markers of cellular
activity, acute phase reactants and enzymes [7–11]. The tumor
marker Cancer antigen 125 has been proposed as a useful diag-
nostic tool for tuberculosis [12].
Cancer antigen 125 or carbohydrate antigen 125 is a high
molecular weight glycoprotein (200 KDa) which was identiﬁed
on the surface of the ovarian carcinoma cell line OVCA 433 by
Bast et al. in 1981 [13].
Ca 125 is most consistently elevated in epithelial ovarian
cancer, but can be expressed in a number of gynecologic (endo-
metrial, fallopian tube) and non-gynecologic (pancreatic,
breast, colon and lung) cancers [14].
High levels of Ca-125 have been reported in patients with
pulmonary and extra-pulmonary tuberculosis, including pleu-
ral, peritoneal, pelvic, miliary, and intraabdominal disease
[15–19].
In pulmonary TB, it was claimed that raised levels of Ca
125 can greatly increase the likelihood of tuberculosis activity
[20]. The diagnostic value of Ca-125 to help differentiate pul-
monary tuberculosis from other pulmonary infections has been
poorly studied [15–17].Aim of the work
The aim of this study was to detect:
1. The role of Ca-125 in differentiating active pulmonary
tuberculosis from other pulmonary infections.
2. The value of Ca-125 as an indicator of response to anti-
tuberculous drugs among patients with active pulmonary
tuberculosis.
Subjects and methods
This study was performed at Minia Chest hospital and Minia
University hospital from November 2011 to December 2012.
This study was approved by the ethics committee of Facultyof Medicine, Minia University and a written consent was ob-
tained from patients and controls. Eighty subjects partici-
pated in this study and were divided into the following
groups:
Group (A): Included (27) patients with active pulmonary
tuberculosis (14 males/13 females, mean age 36.5 years with
range of 15–70). Active pulmonary TB was diagnosed based
on clinical, radiological and bacteriological ﬁndings [21]. This
group had a clinical symptoms of active pulmonary TB in the
form of cough (subacute in 17 patients and chronic in 10 pa-
tients), hemoptysis (6 patients), fever (22 patients), loss of
appetite (20 patients), weight loss (17 patients), night sweats
and malaise (24 patients). Also, some patients had dyspnea
(18 patients).
Radio-logically, this group had lung parenchymal abnor-
malities in the form of patchy shadows and cavitations. Pa-
tients were classiﬁed according to the National Tuberculosis
Association of the USA [22] based on radiological extent of
TB into (20) patients with moderate advanced and (7) patients
with a far advanced lesions on chest X-ray. Bacteriologically,
all of these groups had a sputum smear positive for acid-fast
bacilli (AFB). Acid-fast bacilli stains were performed accord-
ing to the Ziehl–Neelsen method. None had a previous history
of pulmonary or extra-pulmonary TB.
All patients in this group received anti-tuberculous drugs in
the form of (2 months of rifampicin, isoniazide, pyrazinamide
and ethambutol followed by 4 months of rifampicin and iso-
niazide). After 2 months of treatment, sputum smears were re-
peated and conversion into sputum smear negative occurred in
all patients.
Group (B): Included (33) patients with other pulmonary
infections who had a history of cough and expectoration, pul-
monary inﬁltrate ± fever. They were divided into two sub-
groups: group (B1) included (17) patients with community
acquired pneumonia (CAP) (male/female: 11/6, mean age
42.1 years with range of 19–57) and group (B2) who were
(16) patients with acute exacerbation of chronic obstructive
pulmonary disease (AECOPD) (male/female: 11/5, mean age
55.4 years with range of 43–65).
All group B patients had negative sputum smear for acid
fast bacilli.
Control group, group (C): Comprised (20) healthy individ-
uals (male/female: 11/9, mean age 34.8 years and range 19–57).
They had no history of TB or other diseases and their chest X-
rays were normal.
Patients with liver cirrhosis, ascites, renal failure, heart fail-
ure (left sided heart failure), those with known malignancy
anywhere, patients with benign gynecological lesions as pelvic
inﬂammatory disease (PID) or malignant gynecological tu-
mors, pregnant, and menstruating females were excluded. It
is reported that Ca 125 increases in these conditions [23].
All the three groups were subjected to history taking, gen-
eral and local chest examination. Blood sampling for routine
investigations (complete blood count, ESR for group A) and
measurement of serum levels of Ca-125 were performed. Five
ml of venous blood was drawn from each subject. Blood sam-
ples were left to clot for 15–20 min at 37 C, then centrifuged
at 3000 rpm for 20 min. Expressed serum was frozen at -
40 C till the time of Ca-125 assay.
Serum levels of Ca-125 were measured using VIDAS Ca























Figure 1 Mean serum Ca 125 among the studied groups.
Table 1 Pre and post treatment Ca 125 among patients with active pulmonary TB.
No. of cases Serum Ca-125 P
Range Mean ± SD
Before treatment 27 10.6–825 93.5 ± 158.9 0.001
After 4 months of anti-TB drugs 23 4–100 22.8 ± 25.6
Table 2 Correlation co-efﬁcient (r) between Ca 125 and
radiological extent in patients with active pulmonary TB.
Radiological extent No. of cases r-value P
Moderate advanced 20 0.56 0.003
Far advanced 7
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ment of OC125 antigenic determinants in human serum using
Enzyme Linked Fluorescent Assay (ELFA). The results were
automatically calculated by the instruments and the concentra-
tions were expressed in U/ml.
Another assessment of serum Ca-125 was detected among
group (A) only after 4 months of anti-tuberculous drugs.
Statistical analysis
Data were analyzed statistically by SPSS software version 14.
Qualitative data were expressed as number and percentage
whereas quantitative data were summarized as mean ± stan-
dard deviation (SD). Student’s t-test was used when comparing
the means of quantitative data. Correlations between data
were analyzed using Spearman correlation test. For all analy-
ses, statistical signiﬁcance was deﬁned as P values 60.05.
Results
Fig. 1 shows mean serum Ca 125 levels among the studied
groups. It was found that mean Ca 125 levels were signiﬁcantly
higher among group A (93.5 ± 138.9 U/ml) compared to
healthy controls (10.5 ± 7.3, P= 0.004) and other comparable
groups (B1 = 31.2 ± 34.2, B2 = 28.3 ± 19.9, P= 0.03). On
the other hand there was no signiﬁcant difference between the
values of Ca 125 among group B1 vs. B2 (P= 0.7).
Ca 125 levels were re-assayed after 4 months of anti-tuber-
culous drugs among group A. Twenty-three patients out of 27
could be reassayed and the other 4 failed to show for follow
up. All the 23 patients were sputum smear negative for acid
fast bacilli after 4 months of anti-tuberculous drugs. Table 1
shows pre and post anti-tuberculous drug levels of Ca 125
among group A. Ca 125 was signiﬁcantly lower after treatment
than before (22.8 ± 25.6 vs. 93.5 ± 158.9, P= 0.001).There was a signiﬁcant positive correlation between Ca 125
and radiological extent among group A (r= 0.56, P= 0.003)
(Table 2).
For a value of Ca 125 in the diagnosis of active pulmonary
TB, the sensitivity, speciﬁcity, positive, negative predictive val-
ues and accuracy of Ca 125 were found to be 81.4%, 95%,
95.6%, 79.2% and 87.2%, respectively, among group (A) at
a Ca 125P 34.6 U/ml cut-off value. A ROC curve based on
these data was constructed as shown in Fig. 2,
AUC= 0.95 ± 0.02, 95%CI = 0.91–1.008, P= 0.001.
Discussion
Although serum tumor markers were introduced in clinical use
as biochemicals for monitoring response to therapy and detect-
ing early relapse in malignancies, it has been observed that in-
creased levels of these tumor markers can also be detected in
benign conditions.
It was reported that serum Ca-125 levels were also higher
than normal in patients with pulmonary and extra-pulmonary
tuberculosis and that serum Ca-125 level may be a useful mar-
ker for discriminating between patients with active tuberculo-
sis and those with inactive disease [9,20,26].
The results of this study had shown that serum Ca 125 level
was signiﬁcantly higher in patients with active pulmonary TB















Figure 2 Roc curve of Ca 125 among patients with active pulmonary.
422 A.F. Said et al.Other studies have conﬁrmed high serum Ca 125 levels in
tuberculosis, mainly in extra pulmonary locations with abdom-
inal involvement [19,20,24,25]. In Yilmaz et al. study [20], the
mean Ca-125 level in patients with active pulmonary
tuberculosis was (109.7 ± 86.9 U/ml), while it was
(118.46 ± 248.41 U/ml) in Ozsahin et al. study [26] which are
to some extent close to the value in the present study
(93.5 ± 138.9 U/ml). On the other hand, Kim et al. study [30]
showed a lowermean value of Ca 125 in patients with active pul-
monary TB (54.5 ± 22.4) than in our study. This may be due to
the difference in ways of the diagnosis of tuberculous patients.
They depend on sputum culture while in this research; we de-
pended on sputum smear-probably with a higher bacillary load
than culture.
Ronay et al. [27] determined that Ca-125 was immunohisto-
chemically localized and sharply demarcated around tubercu-
lous granuloma in two patients with peritoneal tuberculosis.
They concluded that a possible explanation for this ﬁnding
was the inﬂammatory mesothelial cell proliferation which
was the source for secretion of Ca 125 in patients with TB.
Another study [28] demonstrated that epitheloid and giant
cells in both pleural effusion and ascites were stained with anti-
bodies to Ca-125 in a patient with pleural and peritoneal
tuberculosis.
Our results showed that Ca 125 was signiﬁcantly lower in
patients with CAP and those with AECOPD than in the pul-
monary TB group.While Ozsahin et al. [26] found that themean
Ca-125 values of other comparable groups (CAP, AECOPD,
pleural –pulmonary malignancy and others), were not statisti-
cally different from the mean value of patients with pulmonary
tuberculosis (P> 0.05). This may be due to the difference in the
severity of the other comparable groups in the two studies as re-
gards the causative organism and the degree of inﬂammation.It was found that there was a highly signiﬁcant decrease of
serum Ca-125 after 4 months of anti-tuberculous drugs than
pretreatment level (22.8 ± 25.6 vs. 93.5 ± 158.9, P= 0.001).
In Yilmaz et al. study [20], measurements of serum Ca-125
were performed before treatment, then at the second, fourth,
sixth months of anti-tuberculous drugs and at the third year
following end of treatment. After 2 months of anti-tuberculous
drugs, serum Ca-125 decreased signiﬁcantly than before
treatment (38.4 ± 30.5 vs. 109.7 ± 86.9 at pretreatment level).
After 4 months of anti-tuberculous drugs, Ca-125 declined to
16.4 ± 13.2 U/ml.
InFortu´n et al. study [12], Ca-125 levels were redetermined in
10 patients out of 35 patients with pulmonary tuberculosis after
2 to 4 months of anti-tuberculous drugs. The mean Ca-125 de-
creased signiﬁcantly after anti-tuberculous therapy
(104.9 ± 136.1 vs. 59.5 ± 88.5 U/ml).
In the present study, it was found that 20 patients (74%) of
active pulmonary tuberculosis had a moderate advanced lesion
on chest X-ray and 7 patients (26%) had a far advanced lesion.
No patients had a minimal lesion on chest X-ray. Ca-125 was
higher among patients with far advanced lesions than moderate
advanced (80.7 ± 48 vs. 50.8 ± 49.5), respectively. Therefore,
we can take Ca 125 as one of the parameters in the assessment
of severity of TB. In addition, there was a signiﬁcant positive
correlation between Ca 125 and radiological extent (r= 0.56,
P= 0.003). These results are in agreement with those reported
byKanagarajan et al. [29], who found that levels ofCa-125 being
highest in cavitary pulmonary TB and in miliary TB. Kim et al.
[30] also found that Ca-125 levels appeared to be highest in pa-
tients with cavitary rather than nodular type and thismay reﬂect
the level or extent of the infection.
In the present study, there was an insigniﬁcant correlation of
age and sex to Ca 125 among all of the studied patients and
Role of cancer antigen 125 in active pulmonary tuberculosis 423healthy controls. It was reported that Ca 125 was higher in pre-
menopausal women than post-menopausal ones [31] while Fort-
u´n et al. [12] found that there was no signiﬁcant correlation
between Ca 125 and gender. In our study, there was also an
insigniﬁcant correlation of ESR to Ca 125 among patients with
active pulmonary TB.
At a serum Ca 125 ofP34.6 U/ml as a cut-off value, it had
sensitivity, speciﬁcity, positive and negative predictive values
and diagnostic accuracy of 81.4%, 95%, 95.6%, 79.2% and
87.2%, respectively, among patients with active pulmonary
TB. Fortu´n et al. [12] used a cut-off value of Ca-125 for TB diag-
nosis of 32.5 IU/ml, with sensitivity, speciﬁcity, positive predic-
tive value and negative predictive value of 68.6%, 77.8%, 66.7%
and 79%, respectively.
For estimation of the activity of TB,Yilmaz et al. [20] found a
sensitivity and speciﬁcity of Ca 125 to be 97.5% and 100%,
respectively at a 31 U/ml cut-off point.
In conclusion, the present study shows that serumCa 125 lev-
els in patients with active pulmonary tuberculosis are signiﬁ-
cantly higher than those observed in patients with other causes
of pulmonary infections.
Ca 125 measurement may be recommended if pulmonary
tuberculosis is suspected clinically and radio logically, acid fast
bacilli stain of respiratory samples is negative, patients had a
dry cough (with no sputum specimens available) or in children
in whom the diagnosis of TB is difﬁcult.
Ca-125 has a high sensitivity and speciﬁcity in the estimation
of active pulmonary tuberculosis. So, if Ca-125 level is<34.6 U/
ml in a suspected pulmonary tuberculosis case, one should
prompt a search for alternate diagnosis than TB. It is deﬁnitely
useful in the monitoring of therapeutic responses to anti-tuber-
culoussis drugs, predicting the prognosis and spotting those pa-
tients who are not going to respond early to anti-tuberculous
drugs for whom 2nd line of anti-tuberculous drugs or the new
line of treatment is started early.Conﬂict of interest
None declared.
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